Full Text
Cost-Effectiveness Analysis of Nilotinib Versus High-Dose Imatinib for the Second-Line Treatment of Chronic Myeloid Leukemia In China - Based on Nation-Wide Data

Abstract

Authors

L Guan C Huang Y Liu

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×